Two Compounds, Two Stages of Development Survodutide is further along in trial development than many newer GLP-1/GIP candidates, but it remains behind tirzepatide in terms of published, peer-reviewed volume
If prescribed off-label for weight loss or PCOS alone, coverage is frequently denied
Some struggle with nutrient absorption, distribution, metabolism, or excretion
Semaglutide: The Direct Comparison# Semaglutide is the only GLP-1 drug available in both oral and injectable forms at weight-management doses, enabling direct comparison: The OASIS 1 trial showed that high-dose oral semaglutide (50 mg daily) achieves weight loss comparable to injectable semaglutide (2.4 mg weekly)
32 However, the patients in this population had various confounding diseases